Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan + tetracycline dual therapy vs PPI-based bismuth quadruple therapy for first-line Helicobacter pylori eradication in penicillin-allergic patients
ChiCTR2400085879Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vonoprazan in Helicobacter pylori infection (3 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Eradication rates of Helicobacter pylori. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2400085879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085879.